Contribute Try STAT+ Today

Dr. Padmanee Sharma was in a rush: On Sunday afternoon she had just finished giving her speech as the winner of the William B. Coley Award for outstanding research in tumor immunology, her cousin was in labor in Sharma’s New York City hotel room (long story), and Sharma’s husband, James Allison, was getting marching orders about where he had to be just in case the call came from Stockholm (It did! Allison had long been considered a favorite for the Nobel prize in medicine since soon after he discovered that blocking an immune cell “checkpoint” called CTLA-4 unleashed the power of the immune system to attack tumor cells).

But after her speech at the Fourth International Cancer Immunotherapy Conference, Sharma, professor of genitourinary medical oncology and immunology at the MD Anderson Cancer Center and a pioneer in studying pre-surgical use of immune checkpoint therapies, sat down with STAT to discuss cancer immunotherapy, her biotech company, and why she’s actually quite fond of old white guys.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.